AN2 Therapeutics Stock Quote ANTX - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

2.68

Bid

2.61

Ask

2.94

Volume

38,981

2.59 Day's Range 2.68

1.91 52 Week Range 22.22

Market Cap

79.942M

Previous Close

2.64

Open

2.65

Last Trade

2.66

Last Trade Time

Financial Volume

$ 102,693

VWAP

2.6344

Average Volume (3m)

143,496

Shares Outstanding

29,829,040

Dividend Yield

PE Ratio

-1.23

Earnings Per Share (EPS)

-2.17

Revenue

Net Profit

-64.73M

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.an2therapeutics.com

Headquarters

Dover, Delaware, USA

Founded

1970

AN2 Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANTX. The last closing price for AN2 Therapeutics was $2.64. Over the last year, AN2 Therapeutics shares have traded in a share price range of $ 1.91 to $ 22.22.

AN2 Therapeutics currently has 29,829,040 shares outstanding. The market capitalization of AN2 Therapeutics is $78.75 million. AN2 Therapeutics has a price to earnings ratio (PE ratio) of -1.23.

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

Phase 2/3 trial (EBO-301) in treatment-refractory Mycobacterium avium Complex (TR-MAC) continues with Phase 2 topline results expected in summer 2024 and Phase 3 enrollment pause in place during...

Form SC 13G - Statement of acquisition of beneficial ownership by individuals

Form 8-K - Current report

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.17	-5.9649122807	2.85	2.95	2.5	74085	2.7267582	CS
4	0.45	20.1793721973	2.23	3.07	2.06	159643	2.6535419	CS
12	0.12	4.6875	2.56	3.07	1.91	143496	2.32165795	CS
26	-17.18	-86.5055387714	19.86	21.4	1.91	316271	3.64058862	CS
52	-5.45	-67.0356703567	8.13	22.22	1.91	194318	6.26814317	CS
156	-14.17	-84.0949554896	16.85	23.58	1.91	118840	7.68887755	CS
260	-14.17	-84.0949554896	16.85	23.58	1.91	118840	7.68887755	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
WINTWindtree Therapeutics Inc	$ 8.24 (150.46%)	48.57M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NBSTWNewbury Street Acquisition Corporation	$ 0.1349 (92.71%)	122.1k
YIBOPlanet Image International Ltd	$ 2.915 (53.43%)	260.07k
CREVCarbon Revolution Public Ltd	$ 9.00 (45.87%)	8.06M
NMHINatures Miracle Holding Inc	$ 0.2035 (-48.06%)	7.69M
TANHTantech Holdings Ltd	$ 0.2585 (-47.23%)	6.75M
DXCMDexCom Inc	$ 64.00 (-40.66%)	53.92M
PSIGPS International Group Ltd	$ 1.42 (-31.40%)	716.26k
POAIPredictive Oncology Inc	$ 1.36 (-27.27%)	6.02M
SLNASelina Hospitality PLC	$ 0.0305 (-18.88%)	408.61M
BFIBurgerFi International Inc	$ 0.4206 (97.37%)	313.59M
NVDANVIDIA Corporation	$ 113.06 (0.69%)	293.33M
SQQQProShares UltraPro Short QQQ	$ 9.10 (-2.88%)	176.49M
SGMOSangamo Therapeutics Inc	$ 0.8612 (28.15%)	123.71M